.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
Medtronic
Express Scripts
Cerilliant
US Army
Chubb
Argus Health
UBS
Cantor Fitzgerald
Baxter

Generated: September 22, 2017

DrugPatentWatch Database Preview

Exelixis Inc Company Profile

« Back to Dashboard

What is the competitive landscape for EXELIXIS INC, and when can generic versions of EXELIXIS INC drugs launch?

EXELIXIS INC has one approved drug.

There are four US patents protecting EXELIXIS INC drugs.

There are one hundred and thirteen patent family members on EXELIXIS INC drugs in twenty-eight countries.

Summary for Applicant: Exelixis Inc

Patents:4
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Exelixis Inc
CABOMETYX
cabozantinib s-malate
TABLET;ORAL208692-001Apr 25, 2016RXYesNo► Subscribe► Subscribe► Subscribe
Exelixis Inc
CABOMETYX
cabozantinib s-malate
TABLET;ORAL208692-003Apr 25, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
Exelixis Inc
CABOMETYX
cabozantinib s-malate
TABLET;ORAL208692-001Apr 25, 2016RXYesNo► Subscribe► SubscribeYY ► Subscribe
Exelixis Inc
CABOMETYX
cabozantinib s-malate
TABLET;ORAL208692-003Apr 25, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Exelixis Inc
CABOMETYX
cabozantinib s-malate
TABLET;ORAL208692-002Apr 25, 2016RXYesNo► Subscribe► SubscribeY ► Subscribe
Exelixis Inc
CABOMETYX
cabozantinib s-malate
TABLET;ORAL208692-002Apr 25, 2016RXYesNo► Subscribe► Subscribe► Subscribe
Exelixis Inc
CABOMETYX
cabozantinib s-malate
TABLET;ORAL208692-001Apr 25, 2016RXYesNo► Subscribe► SubscribeYY ► Subscribe
Exelixis Inc
CABOMETYX
cabozantinib s-malate
TABLET;ORAL208692-002Apr 25, 2016RXYesNo► Subscribe► SubscribeYY ► Subscribe
Exelixis Inc
CABOMETYX
cabozantinib s-malate
TABLET;ORAL208692-002Apr 25, 2016RXYesNo► Subscribe► SubscribeYY ► Subscribe
Exelixis Inc
CABOMETYX
cabozantinib s-malate
TABLET;ORAL208692-003Apr 25, 2016RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Exelixis Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
2,014,155,378► Subscribe
9,174,947c-Met modulators and methods of use► Subscribe
8,476,298c-Met modulators and method of use► Subscribe
8,178,532c-Met modulators and method of use► Subscribe
8,067,436c-Met modulators and methods of use► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Exelixis Inc Drugs

Country Document Number Estimated Expiration
Japan2007506777► Subscribe
Australia2010204459► Subscribe
Singapore10201609324U► Subscribe
Singapore187060► Subscribe
CroatiaP20110810► Subscribe
Netherlands300678► Subscribe
Israel234097► Subscribe
Denmark2213661► Subscribe
Taiwan201219371► Subscribe
Japan2015096543► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Exelixis Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0067France► SubscribePRODUCT NAME: CABOZANTINIB ET TOUTE FORME THERAPEUTIQUEMENT EQUIVALENTE COUVERTE PAR LE BREVET DE BASE,INCLUANT SES SELS PHARMACEUTIQUEMENT EQUIVALENTS.; REGISTRATION NO/DATE: EU/1/13/890 20140326
00678Netherlands► SubscribePRODUCT NAME: CABOZANTINIB EN ELKE THERAPEUTISCH EQUIVALENTE VORM DAARVAN ZOALS BESCHERMD DOOR HET BASISOCTROOI, WAARONDER FARMACEUTISCH AANVAARDBARE ZOUTEN; REGISTRATION NO/DATE: EU/1/13/890/001-003 20140326
508Luxembourg► SubscribePRODUCT NAME: CABOZANTINIB ET TOUTES LES FORMES THERAPEUTIQUEMENT EQUIVALENTES QUI EN DERIVENT TELLES QUE PROTEGEES PAR LE BREVET DE BASE, Y COMPRIS LES SELS PHARMACEUTIQUEMENT ACCEPTABLES. FIRST REGISTRATION: 20140326
0678Netherlands► SubscribePRODUCT NAME: CABOZANTINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/13/890/001-003 20140326
2014033Lithuania► SubscribePRODUCT NAME: CABOZANTINIBUM; REGISTRATION NO/DATE: EU/1/13/890/001 - EU/1/13/890/003 20140321
2014 00039Denmark► SubscribePRODUCT NAME: CABOZANTINIB, INKLUSIVE FARMACEUTISK ACCEPTABLE SALTE HERAF, HERUNDER CABOZANTINIB (S)-MALAT; REG. NO/DATE: EU/1/13/890/001-003 20140326
0 50007-2014Slovakia► SubscribePRODUCT NAME: CABOZANTINIB; REGISTRATION NO/DATE: EU/1/13/890/001 - EU/1/13/890/003 20140326
2014000091Germany► SubscribePRODUCT NAME: CABOZANTINIB UND JEDES THERAPEUTISCHE AEQUIVALENT HIERVON WIE DURCH DAS GRUNDPATENT GESCHUETZT, EINSCHLIESSLICH PHARMAZEUTISCH ANNEHMBARER SALZE; REGISTRATION NO/DATE: EU/1/13/890/001-003 20140321
2014 00039Denmark► SubscribePRODUCT NAME: CABOZANTINIB, INKLUSIVE FARMACEUTISK ACCEPTABLE SALTE HERAF, HERUNDER CABOZANTINIB (S)-MALAT; REG. NO/DATE: EU/1/13/890/001-003 20140321
0140029 00117Estonia► SubscribePRODUCT NAME: KABOSANTINIIB;REG NO/DATE: K(2014)2043 (LOPLIK) 26.03.2014
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Harvard Business School
Fuji
Healthtrust
Baxter
QuintilesIMS
Julphar
Federal Trade Commission
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot